questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
One-carbon group transferases
Methyltransferases
Protein Methyltransferases
Histone méthyltransférases
Histone-lysine N-methyltransferase
Histone-lysine N-methyltransferase : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Histone-lysine N-methyltransferase : Questions médicales les plus fréquentes",
"headline": "Histone-lysine N-methyltransferase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Histone-lysine N-methyltransferase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-29",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Histone-lysine N-methyltransferase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Histone méthyltransférases",
"url": "https://questionsmedicales.fr/mesh/D000076983",
"about": {
"@type": "MedicalCondition",
"name": "Histone méthyltransférases",
"code": {
"@type": "MedicalCode",
"code": "D000076983",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.555.500.800.200"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Histone-lysine N-methyltransferase",
"alternateName": "Histone-Lysine N-Methyltransferase",
"code": {
"@type": "MedicalCode",
"code": "D011495",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jasmin Mecinović",
"url": "https://questionsmedicales.fr/author/Jasmin%20Mecinovi%C4%87",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Abbas H K Al Temimi",
"url": "https://questionsmedicales.fr/author/Abbas%20H%20K%20Al%20Temimi",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Danny C Lenstra",
"url": "https://questionsmedicales.fr/author/Danny%20C%20Lenstra",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Paul B White",
"url": "https://questionsmedicales.fr/author/Paul%20B%20White",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands. Floris.Rutjes@ru.nl."
}
},
{
"@type": "Person",
"name": "Ping Qian",
"url": "https://questionsmedicales.fr/author/Ping%20Qian",
"affiliation": {
"@type": "Organization",
"name": "Chemistry and Material Science Faculty, Shandong Agricultural University, Daizong Road No.61, Tai'an, 271018, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Acute paronychia in a neonate secondary to clindamycin-resistant Staphylococcus aureus.",
"datePublished": "2022-09-01",
"url": "https://questionsmedicales.fr/article/36047838",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/pde.15017"
}
},
{
"@type": "ScholarlyArticle",
"name": "Culture-based determinants and outcome of Staphylococcus aureus bloodstream infections.",
"datePublished": "2022-07-22",
"url": "https://questionsmedicales.fr/article/35973315",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.diagmicrobio.2022.115772"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genomic alterations involved in fluoroquinolone resistance development in Staphylococcus aureus.",
"datePublished": "2023-07-26",
"url": "https://questionsmedicales.fr/article/37494330",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0287973"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fucoxanthin Potentiates the Bactericidal Activity of Cefotaxime Against Staphylococcus aureus.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37365295",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00284-023-03381-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "The complex regulation of competence in Staphylococcus aureus under microaerobic conditions.",
"datePublished": "2023-05-12",
"url": "https://questionsmedicales.fr/article/37173437",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s42003-023-04892-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "One-carbon group transferases",
"item": "https://questionsmedicales.fr/mesh/D019875"
},
{
"@type": "ListItem",
"position": 6,
"name": "Methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D008780"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protein Methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D011496"
},
{
"@type": "ListItem",
"position": 8,
"name": "Histone méthyltransférases",
"item": "https://questionsmedicales.fr/mesh/D000076983"
},
{
"@type": "ListItem",
"position": 9,
"name": "Histone-lysine N-methyltransferase",
"item": "https://questionsmedicales.fr/mesh/D011495"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Histone-lysine N-methyltransferase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Histone-lysine N-methyltransferase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Histone-lysine N-methyltransferase",
"description": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?\nQuels tests sont utilisés pour évaluer l'activité des N-méthyltransférases ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux N-méthyltransférases ?\nPeut-on utiliser l'imagerie pour diagnostiquer des anomalies ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Histone-lysine N-methyltransferase",
"description": "Quels symptômes sont liés à une dysfonction des N-méthyltransférases ?\nLes symptômes sont-ils spécifiques à une maladie ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes peuvent-ils évoluer avec le temps ?\nLes symptômes sont-ils visibles à l'examen physique ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Histone-lysine N-methyltransferase",
"description": "Peut-on prévenir les dysfonctionnements des N-méthyltransférases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes exercices physiques aident-ils à prévenir les dysfonctionnements ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Histone-lysine N-methyltransferase",
"description": "Quels traitements ciblent les N-méthyltransférases ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Histone-lysine N-methyltransferase",
"description": "Quelles complications peuvent survenir avec des dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il des complications neurologiques possibles ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications liées aux N-méthyltransférases ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Histone-lysine N-methyltransferase",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes maladies chroniques sont-elles des facteurs de risque ?\nY a-t-il des facteurs génétiques impliqués ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des N-méthyltransférases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques et des méthodes de chromatographie peuvent être employés."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être nécessaires pour évaluer les modifications épigénétiques."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux N-méthyltransférases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de méthylation des histones peuvent servir de marqueurs biologiques."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des anomalies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer ces anomalies."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction des N-méthyltransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de l'expression génique peuvent entraîner divers symptômes, selon le tissu."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils spécifiques à une maladie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils peuvent varier selon la maladie et le type de tissu affecté."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines dysfonctions peuvent entraîner des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils évoluer avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'évolution des symptômes dépend de la progression de la maladie sous-jacente."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils visibles à l'examen physique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les symptômes ne sont pas visibles et nécessitent des tests spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des N-méthyltransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains agents chimiques et toxines peuvent influencer la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages peuvent être utiles pour les personnes à risque génétique élevé."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer la santé épigénétique et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les exercices physiques aident-ils à prévenir les dysfonctionnements ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut avoir un impact positif sur la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les N-méthyltransférases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des N-méthyltransférases sont en cours de développement."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique pourrait corriger les anomalies liées aux N-méthyltransférases."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comme tout traitement, des effets secondaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité à long terme dépend de la maladie et de la réponse individuelle au traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des dysfonctionnements ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des cancers et d'autres maladies génétiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques possibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison de modifications épigénétiques."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent significativement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux N-méthyltransférases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et l'exposition à des agents environnementaux sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dysfonctionnement enzymatique augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques sont-elles des facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies chroniques peuvent prédisposer à des dysfonctionnements enzymatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques peuvent augmenter le risque de dysfonctionnement."
}
}
]
}
]
}
Paronychia is a common inflammatory condition of the nail fold that is often associated with infection. Causes can be fungal, viral, or most commonly, bacterial. Neonatal paronychia is a rare presenta...
The objective of this study was to examine the occurrence, determinants, and outcome of S. aureus bloodstream infections (BSI) diagnosed based on single versus multiple positive initial cultures....
All adults with first episodes of mono-microbial S. aureus BSI in Queensland during 2000-2019 were included....
10,855 (67%) and 5,421 (33%) were diagnosed based on one and multiple positive initial cultures, respectively. Patients with multiple positive initial cultures were significantly younger, more likely ...
Among patients with S. aureus BSI, those diagnosed by single positive initial blood cultures have different clinical features and a higher risk for death....
Fluoroquinolone (FQ) is a potent antibiotic class. However, resistance to this class emerges quickly which hinders its application. In this study, mechanisms leading to the emergence of multidrug-resi...
S. aureus ATCC 29213 was serially exposed to ciprofloxacin (CIP), ofloxacin (OFL), or levofloxacin (LEV) at sub-minimum inhibitory concentrations (sub-MICs) for 12 days to obtain S. aureus -1 strains ...
A strong and irreversible increase of MICs was observed in all applied FQs (32 to 128 times) in all S. aureus-1 and remained 16 to 32 times in all S. aureus-2. WGS indicated 10 noticeable mutations oc...
The emergence of MDR S. aureus was associated with the mutations in the FQ-target sequences and the overexpression of efflux pump systems and their regulators....
The increasing prevalence of antimicrobial resistance (AMR) in Staphylococcus aureus against commonly used antibiotics is a major global health issue. To prevent the emergence of AMR and maintain the ...
To perform natural transformation, one of the three main Horizontal Gene Transfer mechanisms, bacteria need to enter a physiological differentiated state called genetic competence. Interestingly, new ...
Platelets are recognized as key immune effectors, but they are targets of bacterial virulence factors. In the present study, we aimed to examine the relationship between early platelet dynamics and th...
Electronic medical records of adult patients hospitalized for SAB between July 2012 and November 2020 were retrospectively reviewed for relevant demographic, laboratory, and clinical data. The outcome...
Among the 811 patients evaluated, 29% experienced thrombocytopenia on Day 1. Platelet count nadir occurred on Days 2-3 following SAB onset, and Day 4 was a determining point of platelet count trajecto...
Early platelet dynamics during SAB have prognostic significance and represent an early window for potential platelet-directed therapeutic interventions to improve outcome....
The aim was to compare the incidence of Staphylococcus aureus bacteremia in COVID-19 and non-COVID-19 adult patients during the pandemic period versus the previous two years. Also, we described the ch...
Retrospective study in our tertiary-care centre reviewing S. aureus bacteremia episodes in COVID-19 and non-COVID-19 patients through clinical records and the Microbiology Department database....
In 2018 and 2019, the incidence of S. aureus bacteremia episodes was 1.95 and 1.63 per 1000 admissions respectively. In the pandemic period, global incidence was 1.96 episodes per 1000 non-COVID-19 ad...
We showed a significantly high rates of S. aureus bacteremia incidence in COVID-19 patients and higher methicillin resistance and 15-day mortality rates than in non-COVID-19 patients....
The primary host response to Staphylococcus aureus infection occurs via complement. Complement is an elegant evolutionarily conserved system, playing essential roles in early defences by working in co...
Retrospective cohort study....
The aim was to compare the influence of 2 common vertebral osteomyelitis (VO) causing pathogens on treatment failure within the first year of diagnosis....
VO is mainly caused by Staphylococcus aureus (SA), while enterococci and streptococci (ENST) are also responsible for a significant proportion of VO, particularly in elderly patients. Data on VO cause...
We conducted a retrospective monocentric study including VO patients from 2008 to 2020. Primary outcome was treatment failure defined as death or relapse within 1 year (T1). We compared patients diagn...
Data of 130 VO patients (SA=95; ENST=35) were available at T1. Treatment failure occurred in 37% of SA patients and 23% of ENST patients. On multivariate analysis SA [odds ratio (OR): 3.12; 95% confid...
In our cohort every third patient with VO caused by SA or ENST dies within 1 year. Our findings indicate that patients with VO caused by SA, concomitant IE and/or a high Charlson comorbidity index sco...
Staphylococci and streptococci are the most frequent pathogens isolated from prosthetic joint infections (PJIs). The aim of this study was to analyze the outcome of streptococcal and methicillin-susce...
All monomicrobial streptococcal and MSSA PJIs managed in a French Referral Center (2010-2017) were sampled from the prospective PJIs cohort study. The primary outcome of interest was the cumulative re...
Two hundred and nine patients with 91 streptococcal and 132 staphylococcal infections were analyzed. Patients with streptococcal PJI were older, and infection was more frequently hematogenous. Reinfec...
Reinfection-free survival after DAIR and SAT was better for patients with streptococcal than those with MSSA PJIs. No difference was observed after prosthesis exchange....